Agreement with Gr ünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)

AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news